Pfizer just issued an upbeat 2025 profit outlook
Pharma stocks Pfizer Inc (NYSE:PFE) and Teva Pharmaceutical Industries Ltd (NYSE:TEVA) are in the spotlight today. The former's 2025 profit outlook came in above expectations, and the latter's drug with Sanofi (SNY) met the main goal of a mid-stage trial of being an effective treatment for Crohn's disease and ulcerative colitis.
PFE was last seen up 3.7% at $26.18, chipping away at its 12.9% year-to-date deficit. A floor at $25 contained the equity's most recent pullback, while above the 40-day moving average is getting tested today.
TEVA is up a 20% at $19.80 at last glance, trading at its highest level since February 2019 and on track for its best single-day percentage gain day since July 2022. The shares are bouncing off support at the $16 region now boast an 89.2% year-to-date lead.
Both equities are attracting attention in the options pits today. For PFE, 38,000 calls have been traded so far, double the volume typically seen at this point. The most active contract is the December 12.50 call. For TEVA, overall options volume is already running at 19 times the intraday average volume, with the December 20 put leading the charge.